CALIXAR has recently joined the Enterprise European Network to bring its knowledge of native membrane proteins to European research.
CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens. Thanks to its fully native approach CALIXAR gave the opportunity to its partners to work with high-quality and reliable targets or antigens and open new therapeutic pathways.
The company works currently on a new pipeline of highly druggable membrane protein targets and native antigens. These novel targets could significantly improve the success rate of clinical studies and open new therapeutic pathways (drug discovery, antibodies, development, screening of small molecules, …) involving GPCRs, Ion channels and transporters.
CALIXAR is open to participate and develop European projects based on membrane proteins and is looking forward to collaborating with other European research actors.
About Enterprise Europe Network
The Enterprise Europe Network helps companies to innovate and grow on an international scale. It is the world’s largest support network for small and medium-sized enterprises (SMEs) with international ambitions.
The Network is active in over 60 countries worldwide. It brings together 3,000 experts from more than 600 member organisations – all renowned for their excellence in business support.